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1. SUMMARY 
There is currently an important clinical worldwide challenge around the infections produced 
by multidrug-resistant bacteria. The discovery of effective antibiotics has diminished a lot in recent 
years, evidencing a great threat and an urgent need of new and safer antibiotics with broader 
spectrum to fight against these bacteria. 
A new field of study consists in reconsidering polymyxin, a cyclopeptide that presents 
excellent antimicrobial activity against Gram-negative bacteria. However, its use has been 
reduced over the years due to their neuro and nephrotoxicity, so that they are currently used only 
as a last resort antibiotic. As a consequence, one of the research areas consists in the synthesis 
of polymyxin analogs with the aim of improving its biological activity and reducing its toxicity.  
Regarding this work, three polymyxin analogs are firstly synthesized by solid phase peptide 
synthesis using Fmoc/tBu orthogonal protection strategy. Secondly, cyclization is carried out by 
the oxidation between two cysteine residues and finally, the analogs obtained are characterized 
by using RP-HPLC and ESI mass spectrometry. Moderately good yields and high purity are 
obtained for the analogs synthetized.  
Subsequently, the microbiological activity of the analogs is evaluated by determining their 
minimum inhibitory concentration (MIC) and, later, their hemolytic activity is studied as a toxicity 
test. 
Keywords: resistant bacteria, polymyxin analogs, solid phase, microbiological activity, toxicity. 
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2. RESUM 
Actualment hi ha un repte clínic important a nivell mundial al voltant de les infeccions 
produïdes per bacteris resistents a múltiples fàrmacs. El descobriment d’antibiòtics eficaços ha 
disminuït molt en els últims anys, posant en evidència una gran amenaça i una necessitat urgent 
d’antibiòtics nous, de més ampli espectre i més segurs per tal de combatre aquests bacteris. 
Un nou camp d’estudi es basa en la reconsideració de la polimixina, un ciclopèptid que 
presenta una excel·lent activitat antimicrobiana contra bacteris Gram-negatius. No obstant això, 
el seu ús ha disminuït al llarg dels anys a causa de la seva neuro i nefrotoxicitat, de manera que 
actualment s’utilitzen com antibiòtics d’últim recurs. Com a conseqüència, una de les àrees de 
treball consisteix en la síntesis d’anàlegs de polimixina amb l’objectiu de millorar la seva activitat 
biològica i reduir-ne la toxicitat. 
Pel que fa aquest treball, primerament es sintetitzen tres anàlegs de polimixina mitjançant la 
síntesis de pèptids en fase sòlida utilitzant l’estratègia de protecció ortogonal Fmoc/tBu. En segon 
lloc, la ciclació es dur a terme mitjançant l’oxidació de dos residus de cisteïna i, finalment, els 
anàlegs obtinguts es caracteritzen utilitzant RP-HPLC i espectrometria de masses ESI. Els 
anàlegs sintetitzats s’obtenen amb rendiments moderadament alts i alta puresa. 
Posteriorment, s’avalua l’activitat microbiològica dels anàlegs determinant la seva 
concentració mínima inhibitòria (CMI) i, després, s’estudia la seva activitat hemolítica com a prova 
de toxicitat. 
Paraules clau: Bacteri resistent, anàlegs de polimixina, fase sòlida, activitat microbiològica, 
toxicitat. 
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3. INTRODUCTION 
One of the major threats in the field of health worldwide is due to the increase in multidrug-
resistant bacteria to existing drugs. This resistance is mostly caused by irreversible mutations in 
bacterial genes, resulting in bacteria acquiring multiple resistance mechanisms, thus becoming 
resistant to several antimicrobial agents. As a result, this may seriously limit the available 
treatments for current and future infections, increasing the healthcare cost. [1] 
Between 1940 and 1970 the pharmaceutical industry released a steady flow of new 
antibiotics, including several with new mechanisms of action against bacterial resistance. 
However, the number of discoveries has drastically declined in the last few years. [2] 
The growing gap between the increasing frequency of infections caused by multidrug-
resistant bacteria and the decline in research is leading a crisis that must be addressed as a 
matter of urgency. The main goal is to design new antibiotics with a higher spectrum of action and 
security in order to combat bacteria that are prone to acquiring resistance to the antibiotics 
currently on the market. [3] 
3.1. PEPTIDES AS ANTIBIOTICS  
Historically, peptides have not been considered as successful therapeutic candidates due to 
their low oral bioavailability, since they are degraded and eliminated from the bloodstream quickly. 
Its expensive synthesis has also been one of the disadvantages. Despite this, its interest has 
increased in recent years by placing them as therapeutic candidates reconsidering their 
advantages; high efficiency, selectivity, specificity, low toxicity and the possibility of creating 
analogs. [4] 
Antimicrobial peptides (AMPs) are a very diverse group of molecules, which are divided based 
on their composition and structure of amino acids. Against the great diversity, most of these 
peptides are composed of positively charges and amphipathic residues. [5] Their mechanism of 
action is based on the ionic and the hydrophobic interactions between the positive residues of 
AMPs and the anionic phospholipid components exposed to the membrane of the bacteria. [6] 
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3.2. SOLID PHASE PEPTIDE SYNTHESIS 
Bruce Merrifield described a revolutionary method in 1969, the solid phase peptide synthesis 
(SPPS). Until that moment, the synthesis processes were very long, slow and with low yields. So 
this new method allowed the cited aspects to be improved. [7] 
Solid phase peptide synthesis is a process which consists in attaching the C-terminal residue 
of the first amino acid with the protected alpha amino group, to a resin. The protective group is 
then removed and the N-protected and C-activated amino acids are incorporated stepwise. The 
cycle is repeated until the peptide sequence is completed.  
For efficacious synthesis, the side chains must remain protected even with the repetitive N-
alpha deprotections. Normally used an orthogonal protection, which consists in the completely 
different conditions that N-alpha protective group and the side chain protecting groups need to be 
eliminated. 
The resin is washed after each step, so the excess of reagents and the impurities, which are 
not attached to the solid support, are removed by vacuum filtration. Finally, once the sequence 





Figure 1. General structure of SPPS (P: protecting group). 
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3.3. POLYMYXINS 
Polymyxins are a group of antimicrobial cyclic lipopeptides discovered in 1947 almost 
simultaneously by three different teams. They are produced by the fermentation of Paenibacillus 
polymyxa and they have a narrow antimicrobial spectrum since they are only active against Gram-
negative bacteria. [9]  
Polymyxins consist of a heterogeneous mixture composed of up to 30 tightly related 
lipopeptides, from which there are two highly well-known for their clinical use: Polymyxin B and 
colistin (Polymyxin E). They share the main structure, with five positive charges due to the amino 
acid Dab, and the only difference being at amino acid 6th. 
Its use has diminished over the years until it has become last-resort antibiotic since some 
reports have shown its toxicity. However, nowadays they have regained a significant interest as 
a result of their high antimicrobial activity and low resistance, as a way to face the challenge of 
multidrug resistant bacteria. [9,10]  
 
3.3.1. General structure 
The general structure of polymyxins consists of a heptapeptide cycle unit to a linear tripeptide 






As shown in Figure 2, an amide bond between the γ-NH2 of Dab-4 and the α-COOH of the 
Thr-10 amino acid closes the cycle, at the same time it binds to the tripeptide through the α-NH2 
group from Dab-4. Both lipopeptides differ in position 6, in PxB it is occupied by (D)-Phe and (D)-
Figure 2. Polymyxin B1 structure. Amino acid positions are numbered from 1 to 10. The 
fatty acyl moiety and amino acids in the 6th and 7th position, define the hydrophobic 
features of the molecule. The rest of the amino acid residues are polar (Thr) and 
amino-containing basic residues (Dab). 
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Leu in colistin. [9] This presence of lipophilic and hydrophilic groups converts polymyxins into 
amphipathic molecules, and essential property for antibacterial activity. [11] 
3.3.2. Antibacterial mechanism 
The mechanism of action of polymyxins is based on the interaction with the LPS, the main 
component of the OM of Gram-negative bacteria. This explains the reason why they are 
ineffective in front of Gram-positive bacteria. 
LPS is a structural component composed of three domains: O-antigen, a core of 
polysaccharide and lipid A. Lipid A is the domain responsible for the packing of OM, and is the 
main target for polymyxins. LPS has several anionic charges due to the phosphate groups of the 
lipid A, so an electrostatic interaction with polycationic polymyxins occurred. In this way, a 
displacement of the divalent cations, Ca2+ and Mg2+, which normally confer high rigidity and low 
permeability to OM, is generated. It causes the destabilization of LPS layer and allow the insertion 
of the acyl chain of polymyxin. [9,12] 
The set of electrostatic and hydrophobic interactions causes the disruption of the OM and the 
entrance of polymyxin into the periplasmic space takes places. According to a suggested model, 
once in the periplasmic space, polymyxin will form contacts between the two phospholipid 
interfaces and promote an exchange of anionic phospholipids. As a consequence, the membrane 
lipid composition changes and trigged an osmotic imbalance that leads to cell death. [9] 
However, the exact mode of action has not been described completely because other 
mechanisms involving intracellular targets can also play a role. 
3.3.3. Toxicity 
Toxicity of polymyxins is dose-dependent and reversible one the treatment is discontinued. 
The main adverse side effects of polymyxins are nephro and neurotoxicity. 
The molecular mechanisms of toxicity are not well-understood but it seems to indicate that 
toxicity is related to the amphipathic nature of the molecule, due to the presence of hydrophobic 
residues and specially to the presence of charge Dab side chains at physiological pH. [9,13] 
3.3.4. Polymyxin analogs 
One of the research areas consists in the design of new polymyxin analogs with improved 
activity and reduced adverse side toxic effects. The main goal is to understand the relationship 
between activity and toxicity with the chemical structure of polymyxins. 
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First, it is known that amphipathicity in polymyxins is crucial for their activity. Thus, 
modifications in the 6 and 7 residues of the macrocycle and in the size of the fatty acid are applied. 
Secondly, in order to facilitate the synthesis, the fatty acid can be simplified by a linear one, 
without sterocenter. Finally, the amide bond can be substituted by a disulfide bond which could 
facilitate peptide proteolysis and potentially lower renal toxicity. This change implies modifying 
residues 4 and 10. [9] 
4. OBJECTIVES 
The main objectives in this work are the following: 
 Synthesize three polymyxin analogs to obtain new antibacterial agents by using the 
solid phase peptide synthesis for this end. 
 Purify the peptides obtained by semi preparative HPLC and characterize them by 
the use of analytical HPLC and ESI mass spectrometry. 
 Determine the antimicrobial activity of the analogs in Gram-positive and Gram-
negative bacteria by using MIC test. 
 Evaluate the toxicity of the analogs by in vitro hemolysis assays. 
5. EXPERIMENTAL SECTION 
5.1. MATERIALS 
5.1.1. Solvents, reagents and products 
 
Solvent Quality Brand 
ACN HPLC Fisher 
DCM Synthesis VWR 
DMF Synthesis Carlo Erba 
Et2O Synthesis Scharlau 
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H2O Mili-Q - 
MeOH HPLC Fisher 
(a)DMC is filtered through a column of silica. 
(b)The dried Et2O is kept over sodium. 






















Instrument Brand and model 
Autoclave AUTESTER-E 
Centrifuge Hettich ROTOFIX 32 A and 







-Analytical: Simadzu Serie 20 Prominence, 
with two pumps LC-20AD, automàtic SIL-




-Semipreparative: Waters Delta Prep 3000, 
with a Waters 600E pump and a manual 
sample injector Eaters 712, Water 484 
detector, and a data recordar Pharmacia 
Biotech RED 101. 
Reagent or product Quality Brand 
 
 









Fatty acids Reagent Plus®, 99% Sigma-Aldrich 
DIC Pure, 99% Sigma-Aldrich 
DIEA Reagent Plus®, 99% Sigma-Aldrich 
DMSO Synthesis Acros Organics 
HOBt Pure, 99% Fluka 
MHB  Oxoid 
Ninhydrin Pure Koch-Light 
Piperidine Reagent Plus®, 99% Sigma-Aldrich 
PxE and PxB Reagent Plus®, 99% Sigma-Aldrich 
TFA Reagent Plus®, 99% Sigma-Aldrich 
TIS Pure, 98% Acros Organics 
TRIS  Sigma-Aldrich 
Table 1. Solvents and their specifications. 
Table 2. Reagents for peptide synthesis, products for biological assays and their specifications. 
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Lyophilizer Christ Alpha 1-2 LDplus 
Mass spectrometer Zq-Micromass (wàters) 
Microplate reader Synergy HT 
Sonicator Selecta MEDI-II 
Spectrophotometer Shimadzu UV-1700 PC 
 
5.2. METHODS 
5.2.1. Ninhydrin test 
The ninhydrin test, also known as Kaiser test, is an assay used in SPPS to determine the 
completeness of the amino acid coupling. Ninhydrin reacts with primary amino groups resulting 
in an intense blue color (positive assay). 
To perform the test, three solutions are required: 
-Reagent A: ninhydrin (2.5g) are dissolved in EtOH (50mL). The obtained dissolution must be 
kept protected from light. 
-Reagent B: phenol (50mg) is diluted in EtOH (100mL). Then the solution is filtered. 
-Reagent C: KCN (65mg) is added in H2O (100mL), 2mL of the resultant solution are added in 
100mL of distilled pyridine. Then the solution is filtered. 
To carry out the test, a little part of the peptide-resin cleaned and dried is introduced in a small 
test tube after each coupling. Two drops of each reagent (stated above as A, B and C) are added 
and the tube is heated at 110ºC for 3’ in a sand bath. 
If the dissolution remains yellow (negative assay) means a successful coupling because of 
the absence of free amines, while if the solution turns blue (positive assay) free primary amino 
groups are present and a recoupling step is necessary. 
As shows Figure 3, ninhydrin (1) reacts with a primary amine of an amino acid (2) to form the 
imine (3) by a nucleophilic addition-elimination reaction. After that, a decarboxylation reaction 
produces the imine (5) which reacts with H2O to form an aldehyde and a free amine again (6). 
This latter free amine can react with another equivalent of ninhydrin forming 8, which is the 
responsible compound for blue color. [7] 
 
Table 3. Instrumentation and its specifications. 






The peptides purification is carried out by using a semi-preparative RP-HPLC. In this case, 
the retention time is bigger for non-polar molecules. Moreover, the retention time in presence of 
polar solvents will increase and decrease with hydrophobic solvents. 
The column used is Phenomenex C18 of reverse phase (1x25 cm, 5µm diameter particle). 
The elution is carried out at 2mL/min flow rate with a lineal gradient of 0.1% TFA/H2O (A) and 
0.1% TFA/ACN (B) and UV detection at 220 nm.  
5.2.3. Characterization 
Two techniques have been used to carry out the characterization of the peptides.  
5.2.3.1. Analytical RP-HPLC 
This technique is used to identify and quantify the components of a mixture. The amount of 
sample applied in this case is very small compared to the amount of stationary phase in the 
column. 
The column used is a Nucleosil C18 of reverse phase (0.4x25 cm, 5µm diameter particle). 
The elution is carried out at 1mL/min flow rate with a lineal gradient of 0.045% TFA/H2O (A) and 
0.036% TFA/ACN (B) and UV detection at 220 nm.  
Figure 3. Reaction mechanism of ninhydrin assay. 
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5.2.3.2. Electrospray ionization mass spectrometry 
Mass spectrometry is an analytical technique that converts molecular analytes into ions and 
provides qualitative and quantitative information. The ESI is a soft ionization technique extensively 
used for producing gas phase ions (without fragmentation) of thermally labile large 
supramolecules.  
The samples analyzed are peptide solutions in H2O/ACN (1: 1, v / v). A positive mass 
spectrum is obtained where the signals are caused by ionization with a cation hydrogen, sodium 
or potassium.  
5.3. SOLID PHASE PEPTIDE SYNTHESIS 
5.3.1. Synthesis strategy 
The peptide sequences are manually synthesized by using polypropylene syringes equipped 
with a porous polyethylene filter. After all reactions of coupling, the excess of reagents, solvents 
and other byproducts are removed by vacuum filtration. In this work, the SPPS is carried out by 
Fmoc/tBu strategy. 
5.3.1.1. Loading the resin 
First of all, the BHA commercial resin used (f=0.69 mmol/g) needs a pre-treatment because 
it is stored in a compact form. As a result, an impurity-free resin is obtained. The analogs A and 
B are prepared starting from 252.72 mg of dry resin (0.174 mmol) and C from 122.7mg (0.085 
mmol). The protocol used is described in Table 4. 









Step Reagent Time [min] 
1 DCM 5x0.5 
2 40% TFA/DCM 1x1 
3 40% TFA/DCM 2x10 
4 DCM 5x0.5 
5 5% DIEA/DCM 3x2 
6 DCM 5x0.5 
Table 4. Protocol used to load BHA resin. 
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5.3.1.2. Reference amino acid coupling 
The amino acid Fmoc-Val-OH is used as reference amino acid in the synthesis of the three 
analogs. The coupling protocol used is shown in Table 5. 
5.3.1.3. Rink Linker incorporation 
After the Fmoc removal, the RL incorporation is carried out by following the protocol shown in 
Table 5 and by substituting Step 2 for the addition of 1.8 eq. of HOBt, DIC and RL to the BHA 
resin overnight. 
5.3.1.4. Elongation of the peptide chain 
It is necessary to have the terminal amino group deprotected to perform the peptide chain 
elongation. Then, the first amino acid of the chain and the following are coupled in the same way 
as shown in Table 5. The protocol includes the amino acid coupling, the Kaiser test to check the 
coupling and the removal of the Fmoc group. The sequences of the peptides chain of the three 












5.3.1.5. Fatty acid coupling 
Once the last amino acid is coupled and the Fmoc group is removed, the amount of resin in 
the first syringe (252.72mg of dry resin) is divided in two equal portions in order to perform the 






3 eq Fmoc-AA-OH (a) 
3 eq HOBt  




3 DMF 5x0.5 
4 DCM 5x0.5 
5 Ninhydrin test (b) 1x3 
6 DMF 5x0.5 
7 20% piperidine/DMF 1x0.5 
8 20% piperidine/DMF 2x10 
9 DMF 5x0.5 
(a) The amount of each reactive used depends on the weight of dry resin. The reagents are added to the resin 
with a minimum quantity of DMF.  
(b) If the coupling is not completed, 1.5 eq. of the reagents are added for 30 extra minutes in DMF. 
Table 5. Amino acids coupling protocol by Fmoc/tBu strategy. 
Synthesis and study of antibiotic cyclopeptides  17 
 
analogs A and B. The analog C is synthetized directly in the whole amount of the resin (122.7mg 
of dry resin) in the second syringe. 
The corresponding fatty acid is coupled on the peptidyl-resin of the three analogs. The 
protocol for this coupling is shown in Table 5, by substituting Step 2 for the addition of 5 eq. of 
DIC and 5 eq. of fatty acid to the peptidyl-resin for an hour and skipping Steps 6-9. 
5.3.2. Cleavage from the resin 
Once the analogs are synthesized, the side chains of the amino acids remain protected. The 
objective of this step is to separate the peptide from the solid support while removing the acid-
labile protecting groups of the sidechains. This procedure is carried out by acidolysis with 5mL of 
TFA/TIS/H2O (95: 3: 2, v / v) for 90’ to the peptidyl-resin.  
In this way, the resin is filtered and the combined filtrates are evaporated under a nitrogen 
flow to eliminate TFA. Then, the peptide is isolated by treating the crude product with Et2O in 
order to induce precipitation. The product centrifuged and decanted is left to dry in the air and the 
dry peptide is obtained. This procedure is repeated twice.  
 Cleavage yield: analog A 53% (79.8mg), analog B 59% (89.2mg) and analog C 79% 
(120.3mg) 
5.3.3. Cyclization 
The cyclization of the linear peptide is carried out by dissolving the peptide at a 1.5 mg/mL 
concentration is a solution of DMSO/H2O at 3%. The mixture reactions at RT is monitored by 
analytical RP-HPLC. Finally, when the oxidation reaction is finished, the solution is lyophilized. 
 The cyclized peptides are obtained as oils, for the presence of DMSO, and their 
yields are assumed to be 100%. 
5.3.4. Purification and characterization 
The peptides are purified by RP-HPLC at a semi-preparative scale and the UV detection at 
220 nm. A lineal gradient using a flow range of 2mL/min is used with the following specifications 
in each analog: a lineal gradient from 15% to 30% of (B) for 30’ in analog A and B and 20% to 
35% of (B) for 30’ in analog C. The pure fractions obtained are combined and lyophilized.  
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 Purification yield: analog A 52% (41.8mg), analog B 38% (33.9mg) and analog C 
43% (51.3mg) 
The characterization of purified peptides is performed by analytical RP-HPLC and ESI mass 
spectrometry. In RP-HPLC, a lineal gradient using a flow range of 1mL/min is used from 15% to 
30% of (B) in analog A and B and 20% to 35% of (B) in analog C for 30’ respectively. 
Chromatograms are shown in Appendix 3 and ESI spectra at 4. 
  
5.4. EVALUATION OF ANTIMICROBIAL ACTIVITY 
The MIC values for the analogs and commercial PxE are evaluated in order to compare the 
activity against Gram-negative and Gram-positive bacteria. [14,15]  
5.4.1. Preparation of material and medium 
Different culture mediums of MHB at different concentrations are prepared: 1xMHB (9.6g in 
400mL MiliQ-water), 2xMHB (19.4g in 400mL MiliQ-water) and 1xMHB with Agar (23g MHB in 1L 
MiliQ-water with 6g of Agar). All material and liquid growth medium must be sterilized with 
Autoclave before its use. 
5.4.2. Preparation of bacteria and peptides 
The microorganisms used are Escherichia coli ATCC 25922, Pseudomonas aeruginosa 
ATCC 27853, Acinetobacter baumannii ATCC 19606 and Staphylococcus aureus ATCC 25923. 
These bacteria need to be cultured in MHB overnight followed by MHB with Agar overnight 
culture. The day before the test, bacteria are cultured in test tubes with MHB liquid medium 
overnight. Next day, the absorbance of the suspensions is adjusted to 0.2 at 550 nm.  









m/z 1147.8 (7%, [M+H]+), 
574.5 (85%, [(M+2H)/2]2+), 







m/z 1161.8 (7% [M+H]+), 
581.8 (89% [(M+2H)/2]2+), 
388.0 (100%, [(M+3H)/3]3+), 
291.3 (25%, [(M+4H)/4]4+) 
C >99 24.893 m/z 1237.8 (8%, [M+H]+), 
619.7 (100%, [(M+2H)/2]2+) 
Table 6. Final characterization of synthesized analogs.  
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Figure 4. Microtiter plates design for MIC test. 
For each analog and commercial PxE a solution of 512 μg/mL is prepared and then it is diluted 
in order to obtain a 128 µg/ml solution.   
The stock solution is prepared with MiliQ-water taking into account the current proportion of 
the peptide in the product obtained with the TFA counterions. In the case of commercial PxE, the 
same procedure is performed taking into account that 1 mg of commercial PxE corresponds to 
0.85 mg of free base polymyxin. 
5.4.3. MIC determination 
The determination is carried out in 96-well polypropylene microtiter plates, one for each 
analog and one for polymyxin. Its preparation is explained below and it is shown in Figure 4. To 
add the different volumes a multi-channel pipette is used: 
1) 50μL of 2xMHB in column 1, 50μL 1xMHB in columns 2-11 and 100μL 1xMHB in column 
12.  
2) 50μL of peptide solution in column 1. The mixture in column 1 is stirred and 50 μl of it is 
added to column 2. This process is repeated until column 10. The concentration of peptide in 
each column decreases gradually from 32 μg/mL in column 1 to 0.0625 μg/mL in column 10.  
3) 50μL of bacteria suspension adjusted to 106 CFU/mL in columns 1-11. Each bacteria is 
inoculated in two rows.  
4) Incubation of microtiter plate for 20-22 h at 37ºC. The plates are examined for visible 
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Columns 11 and 12 correspond to positive (MHB and bacteria) and negative (only MHB) 
controls respectively. 
5.5. EVALUATION OF TOXICITY  
The next step is to measure the hemolytic activity of the analogs A and B and compare it with 
the PxE values. The hemolytic activity is examined in rabbit’s blood. [14,15]  
5.5.1. Blood treatment 
It is necessary to wash blood with TBS (10mM TRIS; 150mM NaCl) by the centrifugation of 
blood (10’, 4000 r.p.m., 4ºC), removing supernatant and adding buffer and repeat it three times. 
Finally, the concentrated red cells are obtained and they are adjusted to absorbance 1 at 540 nm 
by adding a variable amount of TBS and one drop of blood. A standard amount of erythrocytes is 
obtained to compare the results. 
The positive control where there is total hemolysis is prepared by the centrifugation of 200 μL 
of red cells during 3’ at 10000 r.p.m. The supernatan is then removed and the erythrocytes pellet 
is dissolved with 200μL of destilled water. 
5.5.2. Preparation of peptide solutions 
For each analog and commercial polymyxin, 1mL of a solution of 2mM is prepared by 
dissolving the correspondent amount of peptide in TRIS buffer. Then, a part of it is diluted in order 
to obtain 0.5mM solution. 
5.5.3. Hemolytic assay 
The assay is carried out in 96-well polyproylene microtiter plates, one for two peptides and 
one for PxE. Its preparation is explained below and it is shown in Figure 5. To add the different 
volumes a multi-channel pipette is used: 
1) 200 μL of red cells adjusted solution to colums 1-9 and 11 in rows A-C and F-H. 200 μL of 
TBS to column 10 in rows A-C and F-H and 200 μL of total hemolysis solution to column 12  and 
rows A-D 
2) Addition of the needed amount of each peptide solution in order to obtain the desired 
concentration in each well. The concentration of peptide in each column increases from 10 μM in 
column 1 to 367 μM in column 10. 










As 0% and 100% hemolysis controls, buffer and erythrocytes in distilled water were employed 
in column 10 and 12 respectively. 
3) Incubation of the plate 1h at 37ºC with agitation 
4) Centrifugation of the plate (10 min, 4000 r.p.m., 4ºC) 
5) Addition of 100μL of each well from the supernatant to a new 96-well plate and reading the 




The principal objective in this work is to synthetize polymyxin analogs using SPPS in order to 
obtain new antimicrobial agents with the intention that its activity and toxicity are improved. 
6.1. DESIGN 
The principal changes between polymyxin and the analogs synthesized are explained in 
section 3.3.4 and are based on modifications in the hydrophobic parts and the cycle closure. 
The differences between polymyxin and the synthetized analogs in this work are the following: 
 Substitution of the amide bond between residues Dab-4 and Thr-10 for a disulfide 
bond which requires Cys-4 and (D)-Cys-10 as new residues. This variation 
maintains the size of the molecule and facilitates the synthetic process. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 4 μL 8 μL 12 μL 20 μL 8 μL 12 μL 24 μL 30 μL 45 μL C0 C Blood C100 
B 4 μL 8 μL 12 μL 20 μL 8 μL 12 μL 24 μL 30 μL 45 μL C0 C Blood C100 
C 4 μL 8 μL 12 μL 20 μL 8 μL 12 μL 24 μL 30 μL 45 μL C0 C Blood C100 
D                       C100 
E                         
F 4 μL 8 μL 12 μL 20 μL 8 μL 12 μL 24 μL 30 μL 45 μL C0 C Blood   
G 4 μL 8 μL 12 μL 20 μL 8 μL 12 μL 24 μL 30 μL 45 μL C0 C Blood   
H 4 μL 8 μL 12 μL 20 μL 8 μL 12 μL 24 μL 30 μL 45 μL C0 C Blood   
Figure 5. Microtiter plates design for hemolysis test. 
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 Substitution of residues 6 and 7 for new ones that increases the hydrophobic cycle 
motif. 
 Substitution of the fatty acid chain by a linear one, without stereocenter, and 
increasing its length from analog A to C to show the hydrophobicity effect. 
The sequences of the analogs and shown in Table 7 and the structures in Appendix 2. 
6.2. SOLID PHASE PEPTIDE SYNTHESIS 
Solid phase peptide synthesis is a process to synthesize peptides that is based on the 
successive incorporation of protected amino acids to an amino acid anchored to a solid suport 
matrix by its C-terminus until the desired sequence is completed. Thus, the peptide is synthesized 
from C-terminus to the N-terminus end. 
6.2.1. Synthesis strategy 
The Fmoc/tBu protection strategy is used during the SPPS. This strategy is used to prevent 
the polymerization of the amino acid, so the base-labile Fmoc group protect temporally the alpha 
nitrogen of the amino acid while the acid-labile tBu group is used in the side chains. It consists in 
an orthogonal protection system, since the side chain remain protected even with the N-alpha 
deprotections and vice versa. [7,8] 
The peptide synthesis is based on the reaction between a carboxylic acid and an amino group 
of and amino acid to form an amide bond. However, activation is required in the acid group, since 
if the two groups react directly the product would not be the expected one, but a stable salt (acid-
base reaction). In order to avoid this, DIC is used as an activate agent to form an O-acylisourea 
which can react with the amine to yield the amide. Nevertheless, this activation increases the 
tendency of racemization, so a nucleophile such as HOBt is added to improve the efficiency of 




A Acyl1- Dab-Thr-Dab-cyclo-[Cys-Dab-R6-R7-Dab-Dab-(D)-Cys] 
B Acyl2- Dab-Thr-Dab-cyclo-[Cys-Dab-R6-R7-Dab-Dab-(D)-Cys] 
C  Acyl3- Dab-Thr-Dab-cyclo-[Cys-Dab-R6-R7-Dab-Dab-(D)-Cys] 
Table 7. Sequence of PxB, PxE and the three analogs synthesized. The fatty acid, R6 and R7 
for each analog cannot be disclosed for confidentiality reasons. 





Finally, the activated carboxylic acid can be attacked by an unprotected amino group of a 





Before the next amino acid coupling the Fmoc group must be removed, so a basic treatment 
such as 20% piperidine/DMF is used as it is explained in Table 5. The mechanism for deprotection 




Following this mechanisms, the synthesis of the analogs was carried out on BHA resin. This 
solid support consists of a benzhydrylamine linker bound to a polystyrene matrix, which need to 
be pre-treated as explained in Section 5.3.1.1. The bond between BHA resin and the peptide 
sequences is highly stable, and is for that reason that a linker was put between the peptide 
Figure 6. Mechanism of carboxylic acid activation and HOBt coupling. 
Figure 7. Mechanism of chain elongation. 
Figure 8. Mechanism of Fmoc deprotection. 
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sequence and the resin. Moreover, the addition of a reference amino acid facilitates the SPPS 




For the elongation of the peptide chain, the procedure indicated in Section 5.3.1.4 was carried 
out. The efficiency of the couplings was controlled by ninhydrin test.  
Once the last amino acid was incorporated in the sequence, fatty acids were coupled in the 
three analogs following the protocol described in Section 5.3.1.5 and the following linear peptide 
chain is obtained. 
As Figure 10 shows, lateral chains remained protected with acid-labile groups, so cleavage 
and full deprotection of the peptidyl-resin was carried out by acidolysis reaction specified in 
Section 5.3.2. During this process, highly reactive cationic species are generated from the 
protecting groups. Unless these species are trapped, side reactions take place. To prevent this, 
nucleophilic reagents (known as scavengers) are added to the TFA to quench these ions. In this 






After deprotection, the two residues of cysteine form a disulfide bond by oxidation at high 
dilution to prevent dimerization of the peptide.  
 
Figure 9. Reference AA and RL coupling to BHA resin. 
Figure 10. Lineal structure of an analog with the lateral chains protected. 





The reaction of cyclization was monitored by analytical RP-HPLC. As shown in Figure 12, 
the disappearance of the peak of the linear peptide and the subsequent emergence of a new peak 







Figure 11. Cyclization of the linear analog by mild oxidizing agent 
Figure 12. Chromatograms of cyclization of analog B. At t=0h the percentage of 
the cyclic peptide was 3% and after 120 h it increased to 98%. 
Cyclic peptide 
Cyclic peptide 
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Finally, the solutions were lyophilized to obtain the crude peptides. 
6.2.2.  Synthesis results 
The cycled peptides are obtained as oils due to the presence of DMSO because it has not 
been eliminated in lyophilization. Then, they were purified and characterized obtaining good 
purities and moderately good yields. The characterization results are shown in Appendices 3 
and 4. 
The partial yields are the following: 










A 53 100 52 28 >99 
B 59 100 38 22 >99 
C 79 100 43 34 >99 
 
 
Synthetic yields are good, despite the many steps and tests that are needed in SPPS and 
therefore it causes the loss of the amount of the product. Also, due to side reactions that no leads 
to the desired product.   
The step of purification is the step with lower yields and in this case indicates that the expected 
products are the main components of crude product, but there are also impurities of bad 
couplings. 
7. MICROBIOLOGICAL ACTIVITY 
7.1. GENERAL ASPECTS 
To evaluate the antibiotic activity of the synthesized peptides MIC tests are performed. These 
tests aim to quantify the lower concentration of an antibiotic that inhibits the visible growth of the 
microbe, which corresponds to the minimal inhibitory concentration (MIC).  
The method used consists of a series of dilutions of the peptide (32-0.0625 μg/mL) in a 
medium of microbial growth that is inoculated with a standardized number of organisms (106 
Table 8. Reaction yields and purity of analogs A, B and C 
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UFC/ml) and its incubated during a time of 20-22 h at 37ºC. Finally, the plates are examined to 
obtain visible evidence of the growth bacteria by turbidity [16,17] 
Accurate control of the concentration of organisms in the growth medium is required in order 
to obtain good and comparable results. In this test, the absorbance is adjusted to 0.2 at 550 nm 
In this way, this procedure helps us to relate the turbidity of the solution with the concentration of 
present bacteria (1.5·108 CFU /ml) 
Despite knowing that polymyxin acts on Gram-negative bacteria, three of these bacteria and 
a Gram-positive bacteria were chosen to make the analysis to confirm their actions. 
7.2. RESULTS AND DISCUSSION 
After the overnight incubation, the MIC values are determined visually using an amplifier to 
observe bacteria growth as evidence by turbidity. The results are shown in Table 9. 
 
  MIC [µg/mL]  
  PxE A B C 
 E. coli 1-0.5 32 32 2 
GRAM - P. aeruginosa 1 >32 16-32 2 
 A. baumannii 1 >32 >32 >32 
GRAM + S. aureus >32 >32 >32 4 
 
 
The MIC results show that the analogs do not improve the effectiveness of PxE in Gram-
negative bacteria. However, analog C is the only one which has improved the activity of PxE in 
Gram-positive bacteria. 
A correlation is observed in the analogs between their fatty acid length and their activity. 
Analog C with the largest hydrocarbon chain presents better antimicrobial activity against Gram-
negative bacteria than analog A and B but without exceeding PxE results. 
The effectiveness against the bacteria A. baumannii could not be improved in any analog. A 
hypothesis of their repetitive ineffectiveness is due to the presence of disulfide bond in the 
analogs. 
Table 9. MIC test results of PxE and three analog synthesized 
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8. HEMOLYSIS ASSAYS 
8.1. GENERAL ASPECTS 
Hemolysis is the rupture of red blood cells and the release of their contents into the 
surrounding fluid. The hemolysis results evaluate hemoglobin release in the plasma, as an 
indicator of red blood cell lysis, after test agent exposure. 
The hemolysis process is strongly influenced by the tonicity of the medium in which 
erythrocytes are placed. For example, if red blood cells are placed in a hypotonic solution such 
as distilled water, the water goes into red blood cells through an osmosis process and it causes 
cell rupture. This process is used to obtain the total hemolysis control in this work. Besides, TBS 
(Tris-buffered saline) which is a useful buffer solution formed by TRIS and NaCl (in order to give 
the isotonic salt concentration), avoids hemolysis caused from medium. Also, TBS is used to 
pretend physiological conditions of most living organisms such as the pH value which range from 
7.4 to 8.0.  
The protocol consists in a series of dilutions of the peptide which are mixed with pre-treated 
blood and incubated for 60 minutes at 37°C. The cells are centrifuged and the absorbance of the 
supernatant, which includes hemoglobin, is measured at 540 nm. A toxicity evaluation is obtained 
from the percentage of lysis cells according to peptide concentration.  
A good antibacterial agent should have low MIC values maintain low hemolytic activity, a 
measure of toxicity. 
8.2. RESULTS AND DISCUSSION 
The results are represented by concentration of each peptide versus the hemolysis 







The dependence between the percentage of hemolysis and the concentration of each peptide 
is shown in Figure 14.  
% hemolysis= 100 x [
(A SAMPLE - A C BLOOD)
(AC100 - A C BLOOD)
] 
Figure 13. Percentage of hemolysis equation. (A:absorbance) 






As shown in Figure 14, the percentage of hemolysis increases with a non lineal tendency. 
Comparing the analogs A and B with PxE, the plot does not shown the expected results. Both 
analogs present a smaller length of fatty acid chain than PxE, so analogs are expected to have 
less hemolytic activity. Analog C has not been tested in this work since it has been previously 
tested.  
By comparing the analogs, the results obtained conclude that there is a correlation between 
the length of their fatty acid and their hemolytic values. The analog C, which is more hydrophobic, 
is also more hemolytic. 
The amphipathicity is important in polymyxin mechanism of action. Polymyxins are cationic 
amphipathic molecules that cause cell membrane damage, suggesting a detergent-like mode of 
action. 
The results are not conclusive since in our analogs three types of structural changes have 
been introduced with the hypothesis of reducing the hemolysis and finally, it is observed that this 
is not the case. It will be necessary to continue studying to which structural change belongs the 
increase in the hemolysis. 
Although in vitro tests give valuable information of toxicity, in vivo studies have to be 
performed to assess the potential application of these compounds. 
 
Figure 14. Plot of peptide concentration vs percentage of hemolysis. The results 
are plotted with the main values and its error. 
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9. CONCLUSIONS  
The conclusions reached in this work are the following: 
 Three new antibacterial agents are obtained by using solid phase peptide synthesis. 
This technique is an effective and manageable methodology that allows to acquire 
the desired peptides with high purities (>99%) and good reaction yields. 
 The MIC determination allows knowing and comparing the antimicrobial activity of 
the different antibiotics. The results meet the expectations since a larger fatty acid 
chain contributes to a better microbiological activity and lower MIC values. The 
analog C presents the best antimicrobial activity for its effectiveness against Gram-
negative bacteria and its improved action against the Gram-positive bacteria 
compared with PxE. 
 The hemolytic assays allow to know and compare the toxicity of different antibiotic 
agents. Analogs A and B have not been successful since they have higher 
hemolytic values than PxE and therefore, they present more toxicity. 
Hence, results conclude that modifications made in polymyxin structure in the present work 
need further increase in microbiological activity and in toxicological properties of polymyxin. 
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Acylx - Dab-Thr-Dab-cyclo-[Cys-Dab-R6-R7-Dab-Dab-(D)-Cys] 
Figure 15. General structure of polymyxin analogs.The amino acids R6, R7 and 
the acyl chain cannot be disclosed for confidentiality reasons. 
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Figure 16. HPLC chromatograms of analogs A, B and C. 
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Figure 17. ESI spectra of analogs A, B and C. 
 
 
